A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Terminated · Phase 1 · NCT02848001
Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
At a glance
- Research payments reported, 2025
- $12,054
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 101
About the trial
- Sponsor
- Celgene
- Tested
- CC-90009 (drug)
- Dates
- Started 2016-11-14; completion 2024-04-11
- Results posted
- Yes
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
From ClinicalTrials.gov, last updated 2025-06-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $12,054 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amer Zeidan Hematology & Oncology · New Haven, CT
- Daniel J. Deangelo, M.D.,PH.D. Hematology & Oncology · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $11,804
- Lee Daeyeol Mms $250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.